Aflibercept shows promise in polypoidal choroidal vasculopathy

November 21, 2014

Patients with polypoidal choroidal vasculopathy may benefit from intravitreal aflibercept.

Patients with polypoidal choroidal vasculopathy may benefit from intravitreal aflibercept (Eylea, Bayer HealthCare). According to a study in Retina, treatment-naïve patients with polypoidal choroidal vasculopathy who received aflibercept demonstrated improved vision at a 6-month follow-up. The therapy was well-tolerated and might also be associated with achieving involution of polyps and reducing exudative findings, according to the researchers.

Sixteen treatment-naïve patients with polypoidal choroidal vasculopathy received intravitreal aflibercept between February 2013 and July 2013.

At 6 months after the initial treatment, a significantly better best-corrected visual acuity was seen, compared with baseline.

In addition:

  • The patients' mean central foveal thickness decreased significantly (from 417 ± 127 μm to 187 ± 50 μm).

  • The patients' mean choroidal thickness decreased significantly (from 250 ± 63 μm to 217 ± 64 μm).

  • A complete resolution was achieved in 14 of 15 cases with subretinal fluid, 3 of 4 cases with fibrin, and 8 of 9 cases with subretinal haemorrhage.

  • Of the 9 cases with pigment epithelial detachment, 5 obtained a complete improvement, and 3 exhibited a partial decrease.

  • Polyps regressed at a rate of 75% (12 out of 16 cases).

To read the abstract of the study, click here.

Related Content:

Articles | Retina